Learning Implementation of Guideline-based Decision Support System for Hypertension Treatment (LIGHT): A Staged Cluster Randomized Trial
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Hypertension
- Sponsor
- China National Center for Cardiovascular Diseases
- Enrollment
- 10000
- Locations
- 3
- Primary Endpoint
- The proportion of visits with ideal appropriate treatment provided among all the eligible hypertension visits within the period of observational follow-up
- Last Updated
- 5 years ago
Overview
Brief Summary
This trial aims to evaluate the effectiveness of a guideline-based decision support system for hypertension management by physicians at primary health care (PHC) centers in China in order to improve the delivery of appropriate treatment and blood pressure (BP) control for hypertensive individuals.
Detailed Description
The LIGHT trial aims to assess the effectiveness of decision support system (DSS) for hypertension treatment in cluster clinics. At each stage, the main randomization will occur at the PHC center level. During the first 3 months (baseline period), the physicians at all sites will use an electronic data collection system to collect information about the individuals who attend the clinic. After site randomization, physicians at control sites will continue to deliver usual care, and physicians at intervention sites will receive training and support on the use of the DSS. And the DSS will recommend antihypertensive medications according to the assigned protocol. All individuals will be asked to attend the clinic at least once every 3 months.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
The proportion of visits with ideal appropriate treatment provided among all the eligible hypertension visits within the period of observational follow-up
Time Frame: Baseline; 1 year
ideal appropriate treatment means guideline-accordant treatment
Secondary Outcomes
- The average change in SBP from first visit after randomization to the last visit among the eligible participants during the period of 9-month observation.(Baseline; 1 year)
- The proportion of visits with acceptable appropriate treatment among all the eligible hypertension visits.(Baseline; 1 year)
- The percentage of participants with BP<140/90 mmHg at the last visit among the eligible participants during the period of 9-month observation.(Baseline; 1 year)